[Medication-induced hyperprolactinemia].
Inoue
Tatsuhide
T
Center of Diabetes, Endocrinology and Metabolism, Shizuoka General Hospital.
D000927:Anticonvulsants / Q000009:adverse effects; D018678:Cholinergic Agents / Q000009:adverse effects; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D018492:Dopamine Antagonists / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects; D006635:Histamine H2 Antagonists / Q000009:adverse effects; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects
D000927:Anticonvulsants; D018678:Cholinergic Agents; D003278:Contraceptives, Oral, Hormonal; D018492:Dopamine Antagonists; D004967:Estrogens; D006635:Histamine H2 Antagonists; D017367:Selective Serotonin Reuptake Inhibitors